Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gaboxadol - Ovid Therapeutics

Drug Profile

Gaboxadol - Ovid Therapeutics

Alternative Names: LU-02030; LU-2-030; MK-0928; OV-101; THIP

Latest Information Update: 16 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Max Planck Institute of Psychiatry
  • Developer Lundbeck A/S; Ovid Therapeutics
  • Class Anaesthetics; Analgesics; Anorectics; Antidepressants; Antiepileptic drugs; Hypnosedatives; Isoxazoles; Pyridines; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome; Angelman syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes - Angelman syndrome; Fragile X syndrome

Highest Development Phases

  • Phase III Angelman syndrome
  • Phase II Fragile X syndrome
  • No development reported Epilepsy
  • Discontinued Insomnia; Major depressive disorder

Most Recent Events

  • 02 Jul 2019 Phase-III clinical trials in Angelman syndrome (In children) in USA (PO) (NCT04106557)
  • 02 Jul 2019 Gaboxadol - Ovid Therapeutics receives Orphan Drug status for Angelman syndrome in European Union
  • 27 Jun 2019 Ovid Therapeutics plans ELARA, an open-label extension trial for Angelman syndrome (Treatment-experienced) in Q1 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top